Henan Tongwei Medical Equipment Co., LtdCall us : +86 − −19139704654 // Email us : [email protected]

MENU China Mining Equipment Industry & Technology Group Co., Ltd.
  • Home
  • Products
  • About
  • Contact

Home / Products

structure-based design of antiviral drug candidates

  • Microorganisms

    Structure-based drug design is key to antiviral development The available cocrystal structures of SARS-CoV-2 3CL pro with different types of inhibitors are critical for improving the potency and understanding the mode of action of inhibitors This approach is also important in fragment-based drug design by providing efficient strategies for

    Get Price
  • Structure Based Drug Design

    Structure-based design of antiviral drug candidates Fragment-based drug discovery is a strategy widely used in both academia and pharmaceutical companies to generate small-molecule protein inhibitors and drug candidates Among the approaches reported in the literature (growing linking and merging) the linking approach

    Get Price
  • Novel Compounds Designed To Inhibit SARS

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease SARS-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak The main protease (Mpro) of SARS-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription

    Get Price
  • Research progress on repositioning drugs and specific

    Jul 08 2020In this review we provide an overview of published scientific information about small molecular anti-SARS-CoV-2 drugs with an emphasis on repositioning antiviral drugs and the novel SARS-CoV-2 specific antiviral drugs for COVID-19

    Get Price
  • 3C

    The protease 3CLpro is a potential drug target for coronavirus infections due to its essential role in processing the polyproteins that are translated from the viral RNA The X-ray structures of the unliganded SARS-CoV-2 protease 3CLpro and its complex with an α-ketoamide inhibitor provides a basis for design of α-ketoamide inhibitors [6] for

    Get Price
  • (KMS): Structure

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease: Wenhao Dai Bing Zhang Xia-Ming Jiang Haixia Su Jian Li Yao Zhao 3 Xiong Xie Zhenming Jin Jingjing Peng Fengjiang Liu Chunpu Li You Li Fang Bai Haofeng Wang Xi Cheng Xiaobo Cen Shulei Hu Xiuna Yang Jiang Wang Xiang Liu Gengfu Xiao Hualiang Jiang Zihe Rao Lei-Ke Zhang

    Get Price
  • Structure Based Drug Design

    Structure-based design of antiviral drug candidates Fragment-based drug discovery is a strategy widely used in both academia and pharmaceutical companies to generate small-molecule protein inhibitors and drug candidates Among the approaches reported in the literature (growing linking and merging) the linking approach

    Get Price
  • Targeting the Dimerization of the Main Protease of

    May 13 2020A new coronavirus (CoV) caused a pandemic named COVID-19 which has become a global health care emergency in the present time The virus is referred to as SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) and has a genome similar (∼82%) to that of the previously known SARS-CoV (SARS coronavirus) An attractive therapeutic target for CoVs is the main protease (Mpro)

    Get Price
  • Lead Optimization for the Antiviral Drug Discovery of

    The higher the quality of preclinical drug candidates the higher the likelihood of successful entry into clinical development Creative Biostructure provides a comprehensive set of structure-based services for the discovery of antiviral agents for treatment of coronavirus infection If you have research needs for optimization of antiviral

    Get Price
  • Lead Optimization for the Antiviral Drug Discovery of

    The higher the quality of preclinical drug candidates the higher the likelihood of successful entry into clinical development Creative Biostructure provides a comprehensive set of structure-based services for the discovery of antiviral agents for treatment of coronavirus infection If you have research needs for optimization of antiviral

    Get Price
  • How structural biology is playing a role to tackle COVID

    May 27 2020Zhang L et al 2020 Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Science doi: 10 1126/science abb3405 Dai W et al 2020 Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Science doi: 10 1126 science abb4489 Gao Y et al 2020

    Get Price
  • Genomics insights of SARS

    Jul 31 2020Coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 is a global health emergency and no clinically approved vaccines or antiviral drugs available to date Intensive research on SARS-CoV-2 is urgently warranted to understand its pathogenesis and virulence mechanisms and to discover target-based antiviral

    Get Price
  • Structure

    Mar 26 2020Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus None of the current DENV antiviral candidates possess potency similar to the approved antiviral drugs which indicates that more efforts and resources must be invested before an effective DENV drug

    Get Price
  • Cyanohydrin as an Anchoring Group for Potent and Selective

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Science 2020 eabb4489 DOI: 10 1126/science abb4489 Rafael Pinto Vieira Viviane Corra Santos Rafaela Salgado Ferreira Structure-based Approaches Targeting Parasite Cysteine Proteases

    Get Price
  • Regulatory updates on China April 2020

    May 04 2020Structure-Based Design of Antiviral Drug Candidates Targets SARS-CoV-2 Main Protease A team of Chinese scientists recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (Mpro) and one of them is a drug candidate for further clinical studies The research published online in Science on 22 April 2020 was conducted by

    Get Price
  • Structure

    Apr 22 2020Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease April 22 2020 A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (M pro) and one of them is a good drug candidate for further clinical studies The research published online in Science on April 22 was conducted by Prof LIU

    Get Price
  • Structure

    Structure-based drug design approach: Screening of ChEMBL antiviral compounds We have screened the ChEMBL database for antiviral drugs that have passed the Lipinski's rule of five (RO5) for drug-likeliness The structure-based drug design approach was taken into consideration using both the S protein and the M pro of SARS-CoV-2 The

    Get Price
  • Recent insights for the emerging COVID

    Jul 04 2020Dai and coworkers had conducted the structure-based design of antiviral agents targeting this protease by parsing out the substrate-binding pocket of M pro In this regard further study targeting such a protease may give rise to certain antiviral drug candidates

    Get Price
  • Structure

    Mar 25 2020Structure-Based Design Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease Wenhao Dai a d † Bing Zhang b † Xia-Ming Jiangc † Haixia Su a † Jian Li a Yao Zhao

    Get Price
  • Structure

    Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease 04-22-2020 Comments Off on Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (M pro ) and one of them is a good

    Get Price
  • Structure

    Apr 22 2020Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Wenhao Dai 1 2 * Bing Zhang 4 * Haixia Su 1 * Jian Li 1 5 Yao Zhao 3 Xiong Xie 1 Zhenming Jin 1 Fengjiang Liu 3 Chunpu Li 1 You Li 6 Fang Bai 3 Haofeng Wang 3 Xi Cheng 1 Xiaobo Cen 6 Shulei Hu 1 Xiuna Yang 3 Jiang Wang

    Get Price
  • Recent insights for the emerging COVID

    Jul 04 2020Dai and coworkers had conducted the structure-based design of antiviral agents targeting this protease by parsing out the substrate-binding pocket of M pro In this regard further study targeting such a protease may give rise to certain antiviral drug candidates

    Get Price
  • Cocrystal Pharma Inc 's Structure

    The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C influenza and norovirus Influenza Program To date Cocrystal's lead influenza molecule in development CC-42344 has shown excellent antiviral activity against influenza A strains including avian pandemic strains and

    Get Price
  • COVID/SARS CoV2 Rapid Research Reports #3 (Virtual)

    Hong Liu Chinese Academy of Sciences Shanghai - Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease Yogesh Gupta University of Texas San Antonio - Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus

    Get Price
  • Structure

    This study shows that structure-based drug design is an effective strategy for designing specific antiviral leads against SARS-CoV-2 Preclinical research on compound 11a is now proceeding The team has decided to share its research data with scientists around the world to accelerate the development of anti-SARS-CoV-2 drugs

    Get Price
  • Structure

    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Wenhao Dai 1 2 * Bing Zhang 4 * Haixia Su 1 * Jian Li 1 5 Yao Zhao 3 Xiong Xie 1 Zhenming Jin 1 Fengjiang Liu 3 Chunpu Li 1 You Li 6 Fang Bai 3 Haofeng Wang 3 Xi Cheng 1 Xiaobo Cen 6 Shulei Hu 1 Xiuna Yang 3 Jiang Wang

    Get Price
  • european resuscitation council covid-19 guidelines

    betreuung von abschlussarbeiten 鈥 institut fr

    journal of medical imaging - spie

    mesh plastic nets from complex plastics toll

    protec systems 鈥 technical sales service company

    Marshall Islands fibers manufacturers exporters suppliers

    china disposable surgical face mask earloop

    china disposable isolation cover all suits for protective

    global powered surgical instruments market outlook

    nist reference fluid thermodynamic and transport

    computer problems solutions for pc download

    melt blown fabric filter - offers from melt blown fabric filter

    conseils pour faire une recherche sur internet

    tyvek over felt - fine homebuilding

    china pfe 99 bfe99 meltblown media

    andy kruse 鈥 regional sales manager 鈥 terumo

    matriel mdical et para mdical gap 05000 - rdv en

    dynarex sterile gauze pads - medical monks

    advanced particulate p100 filter with nuisance level

    eco precision

    china ce en149 disposable ffp1 respirator mask with

    des cahiers de vacances numriques gratuits pour

    paper face mask-china paper face mask

    les 30 meilleures images de porte-monnaie au

    flat mask outer ear loop welding machine

    when should income protection cover be held inside

    american health care workers receive counterfeit n95

    organic cotton face mask 鈥 aplat

Henan Tongwei

Henan Tongwei Medical Device Co., Ltd. is a branch company of Guangzhou Ningwei Technology Co., LTD., which is specialized in the production, processing, sales, research and development and service of related products and equipment in the medical device industry.

Contact Us

  • : Room 810, Block B, Jinzhonghuan Building, Zhengzhou City, Henan Province
  • : +86 19139704654
  • : [email protected]

products

NIOSH N95

Mask Machine

hospital doctor safety ppe coverall medical protection suit with hood

BFE99 Melt Blown Fabric

surgical gown aami level 3

7/24 | Online | Chat | Now TONGWEIMEDICAL © All Rights Reserved.